%0 Journal Article %A E Tuaillon %A K Bolloré %A A Pisoni %A S Debiesse %A C Renault %A S Marie %A S Groc %A C Niels %A N Pansu %A AM Dupuy %A D Morquin %A V Foulongne %A A Bourdin %A V Le Moing %A P Van de Perre %T Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients %D 2020 %R 10.1101/2020.05.04.20090027 %J medRxiv %P 2020.05.04.20090027 %X SARS-CoV-2 antibody assays are needed for serological surveys and as a complement to molecular tests to confirm COVID-19. However, the kinetics of the humoral response against SARS-CoV-2 remains poorly described and relies on the performance of the different serological tests.In this study, we evaluated the performance of six CE-marked point-of-care tests (POC) and three ELISA assays for the diagnosis of COVID-19 by exploring seroconversions in hospitalized patients who tested positive for SARS-CoV-2 RNA.Both the ELISA and POC tests were able to detect SARS-CoV-2 antibodies in at least half of the samples collected seven days or more after the onset of symptoms. After 15 days, the rate of detection rose to over 80% but without reaching 100%, irrespective of the test used. More than 90% of the samples collected after 15 days tested positive using the iSIA and Accu-Tell® POC tests and the ID.Vet IgG ELISA assay. Seroconversion was observed 5 to 12 days after the onset of symptoms. Three assays suffer from a specificity below 90% (EUROIMMUN IgG and IgA, UNscience, Zhuhai Livzon).The second week of COVID-19 seems to be the best period for assessing the sensitivity of commercial serological assays. To achieve an early diagnosis of COVID-19 based on antibody detection, a dual challenge must be met: the immunodiagnostic window period must be shortened and an optimal specificity must be conserved.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04347850Funding StatementFunding. This work was supported by Grants from Montpellier University Hospital and Montpellier University (MUSE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CPP Ile de France, n 2020-A00935-34All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available %U https://www.medrxiv.org/content/medrxiv/early/2020/05/27/2020.05.04.20090027.full.pdf